ABBV-155

DRUG2 trials

Sponsors

AbbVie, Memorial Sloan Kettering Cancer Center

Conditions

Advanced Solid TumorsGlioblastomaGliosarcoma

Phase 1

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

CompletedNCT03595059

AbbVieAdvanced Solid Tumors

Start: 2018-07-13End: 2025-09-12Updated: 2025-12-10

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

RecruitingNCT06934889

Memorial Sloan Kettering Cancer CenterGlioblastoma, Gliosarcoma

Start: 2025-04-07End: 2028-04-01Target: 60Updated: 2026-09-09

Related Papers

Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.

Journal of Clinical Oncology2023-06-0116 citations

A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.

Journal of Clinical Oncology2021-05-2032 citations